1-800-887-8100
COPAXONE® (glatiramer acetate injection) 40 mg/mL Logo
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
MENU
Shared Solutions®
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
For patients with relapsing multiple sclerosis (RMS)
PAST. PRESENT. FUTURE.

An immunomodulator with demonstrated efficacy, safety, and tolerability.1

Going Down

3-TIMES-A-WEEK COPAXONE® 40 mg/mL
THE #1 PRESCRIBED RMS THERAPY IN THE US2†

to get your patient started today

AN RMS TREATMENT CHOICE FOR TODAY
AND TOMORROW

You're focused on their future, and so are we. See our ongoing commitment to relapsing MS patients, backed by patient support and the milestones in the development of COPAXONE®.

A personalized approach
to help patients start and stay
committed to copaxone®  therapy

Teva’s Shared Solutions® program has supported the relapsing MS community for 2 decades and counting.
Trust Teva's Shared Solutions® to partner with you, your patients, and your practice.

A HISTORY MARKED BY INNOVATION

From discovery and development to robust clinical trials, COPAXONE® has a history steeped in scientific
exploration and dedication to relapsing MS care.

References

  1. COPAXONE® (glatiramer acetate injection) Current Prescribing Information. Teva Neuroscience, Inc.
  2. IQVIA Health National Prescription Audit, September 2018. Data proprietary to IQVIA.

Based on IQVIA Health National Prescription Audit, September 2018. Data proprietary to IQVIA.


Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.

IMPORTANT SAFETY INFORMATION

COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of